Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ruff

Showing results (91-100 of 224) with videos related to

Pageof 23
Sort By:
Clinical Pharmacokinetics|March 9, 2016
Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical TrialElke H J Krekels, Ronald Niebecker, Mats O Karlsson, et al.
Journal of the American College of Cardiology|August 6, 2021
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48David D Berg, Robert P Giugliano, Christian T Ruff, et al.
The Journal of Rheumatology|April 5, 2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugsChristian T Ruff, David A Morrow, Peter Jarolim, et al.
Journal of Virology|August 21, 2002
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposureChristian T Ruff, Stuart C Ray, Patricia Kwon, et al.
Journal of the American College of Cardiology|March 18, 2017
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 TrialRaffaele De Caterina, Giulia Renda, Anthony P Carnicelli, et al.
Clinical Cardiology|June 18, 2022
Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitorsBenjamin M Scirica, KyungAh Im, Sabina A Murphy, et al.
Journal of Thrombosis and Thrombolysis|January 19, 2013
Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain studyChristian T Ruff, Marc P Bonaca, Joshua M Kosowsky, et al.
International Journal of Cardiology|February 4, 2018
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trialIlaria Cavallari, Christian T Ruff, Francesco Nordio, et al.
Thrombosis and Haemostasis|May 4, 2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 TrialJames D Douketis, Sabina A Murphy, Elliott M Antman, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
Pageof 23

Showing results (91-100 of 224) with videos related to

Sort By:
Pageof 23
Clinical Pharmacokinetics|March 9, 2016
Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical TrialElke H J Krekels, Ronald Niebecker, Mats O Karlsson, et al.
Journal of the American College of Cardiology|August 6, 2021
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48David D Berg, Robert P Giugliano, Christian T Ruff, et al.
The Journal of Rheumatology|April 5, 2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugsChristian T Ruff, David A Morrow, Peter Jarolim, et al.
Journal of Virology|August 21, 2002
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposureChristian T Ruff, Stuart C Ray, Patricia Kwon, et al.
Journal of the American College of Cardiology|March 18, 2017
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 TrialRaffaele De Caterina, Giulia Renda, Anthony P Carnicelli, et al.
Clinical Cardiology|June 18, 2022
Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitorsBenjamin M Scirica, KyungAh Im, Sabina A Murphy, et al.
Journal of Thrombosis and Thrombolysis|January 19, 2013
Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain studyChristian T Ruff, Marc P Bonaca, Joshua M Kosowsky, et al.
International Journal of Cardiology|February 4, 2018
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trialIlaria Cavallari, Christian T Ruff, Francesco Nordio, et al.
Thrombosis and Haemostasis|May 4, 2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 TrialJames D Douketis, Sabina A Murphy, Elliott M Antman, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
Pageof 23